Medicare Compliance & Reimbursement - 2005 Issue 37
Oncology: Another Nail in Coffin For Cancer Care Next Year
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an HHS Office of Inspector General report and CMS response regarding Medicare reimbursement for oncology-related drugs under the average sales price system. It is relevant to oncology practices, hematology/oncology groups, and medical billing professionals who track Medicare payment policy and drug reimbursement trends. The article covers the audit’s broad findings, the specialties reviewed, and why the report matters for future reimbursement expectations.
Why This Topic Matters
It helps readers understand how a federal audit may affect Medicare drug payment policy for cancer care and why oncology practices should pay attention to reimbursement methodology changes.
What You Will Learn
- What the article says about Medicare drug reimbursement trends in oncology
- Which medical specialties were included in the payment review
- How the HHS Office of Inspector General framed its audit findings
- Why the CMS response is relevant to future oncology payment policy
Who Should Read This
- Oncology physicians
- Hematology/oncology practices
- Medical oncology practices
- Medical coders and billers
- Revenue cycle staff
- Healthcare compliance professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com